New Study Provides Evidence That Diversity Enhances Higher Education Outcomes forbes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forbes.com Daily Mail and Mail on Sunday newspapers.
Jun 01 2021
Opposition to a second Japanese patent, applied for in relation to the use of CRISPR methods in cellular studies, has been rejected by the Japanese Patent Office (JPO), reports ERS Genomics, the Dublin-based company providing access to this technology.
“The JPO actions reinforce the broad and fundamental nature of our CRISPR patent portfolio, both in Japan and worldwide.” Michael Arciero
Japanese patent (JP6692856), filed by CRISPR/Cas9 intellectual property co-owner Dr. Emannuelle Charpentier, together with The Regents of the University of California and University of Vienna (collectively known as CVC), covers compositions and methods for use in a variety of eukaryotic cells, in either dual-guide or single-guide format.
ERS Genomics: Japanese Patent Office Upholds Key Charpentier/Doudna CRISPR Patent and Allows Third streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Arguments filed in opposition to JP6692856 rejected JP2019-210828 represents third Japanese patent ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9